Arcturus Therapeutics (ARCT) closed the last trading session at $10.84, gaining 5.2% over the past four weeks, but there ...

In CF, Arcturus is advancing an inhalable mRNA therapy, ARCT-032, for which it is running a Phase II trial in patients who ...

Q1 2025 Management View Joe Payne, President and CEO, highlighted heightened interest in the company's mRNA therapeutics pipeline, pointing to forthcoming clinical data for both the ARCT-032 cystic ...

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...

Neda Safarzadeh Safarzadeh; Vice President and Head of Investor Relations, Public Relations and Marketing; Arcturus Therapeutics Holdings Inc. Joseph Payne; Presiden ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

During the last three months, 7 analysts shared their evaluations of Arcturus Therapeutics ARCT, revealing diverse outlooks from bullish to bearish. The following table summarizes their recent ...

Arcturus Therapeutics shares have fallen 32% since the beginning of the year. In the final minutes of trading on Monday, shares hit $11.60, a drop of 57% in the last 12 months.

Payne reported the recent EU approval of KOSTAIVE, Arcturus' self-amplifying mRNA COVID-19 vaccine, and receipt of an initial milestone payment from CSL. He announced an upcoming marketing ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Arcturus Therapeutics (ARCT) on Monday reported a loss of $14.1 million in its first quarter. On a per-share basis, the San Diego-based company said it had a loss of ...